Krebs: Woher kommst Du & wohin gehst Du?
Publisher: facultas/maudrich; 28 Sep 2015, ASIN: B015MXVM4C

In Vorbereitung

Ein Biotechkrimi

Das Immunsystem – ein gespannter Bogen


  1. Tumorimmuntherapie mit Dendritischen Zellen: ein neues Behandlungsparadigma für Krebserkrankungen. Journal für Urologie und Urogynäkologie, 9/2009
  2. Dendritische Zellen als neues Behandlungsparadigma. Jatros Hämatologie & Onkologie; 7/2009
  3. Krebsimmuntherapie: dendritische Zellen als neues Behandlungsparadigma. universimed.com; 2/2010
  4. Dendritische Zellen in der Krebsimmuntherapie. Spectrum Onkologie; 4/2010
  5. Das Ende vom Anfang der Krebsimmuntherapie Jatros Hämatologie & Onkologie; 1/2011
  6. Krebsimmuntherapie, ein neues Paradigma in der Krebsbehandlung. Universum Innere Medizin; 2/2011
  7. Neue Hochtechnologiebehandlungen für Krebs. Jatros Hämatologie & Onkologie; 3/2001
  8. Personalisierte Medizin – Revolution in der Behandlung oder „neuer Wein in alten Schläuchen“? Jatros Hämatologie & Onkologie; 6/2001
  9. Immunologie, die Vierte Säule der Krebstherapie. Die Sonne; St. Anna Kinderkrebsforschung; 4/2012
  10. Zellbasierte Therapien in der Onkologie. Universum Innere Medizin; 8/2017


  1. Soukup K, Halfmann A, Le Bras M, et al. The MAPK-Activated Kinase MK2 Attenuates Dendritic Cell-Mediated Th1 Differentiation and Autoimmune Encephalomyelitis. J Immunol 2015;195:541-52.
  2. Buchroithner J, Pichler J, Marosi C, et al. Vascular endothelia growth factor targeted therapy may improve the effect of dendritic cell-based cancer immune therapy. Int J Clin Pharmacol Ther 2014;52:76-7.
  3. Strioga MM, Felzmann T, Powell DJ, Jr., et al. Therapeutic dendritic cell-based cancer vaccines: the state of the art. Crit Rev Immunol 2013;33:489-547.
  4. Luger R, Valookaran S, Knapp N, Vizzardelli C, Dohnal AM, Felzmann T. Toll-like receptor 4 engagement drives differentiation of human and murine dendritic cells from a pro- into an anti-inflammatory mode. PLoS One 2013;8:e54879.
  5. Traxlmayr MW, Wesch D, Dohnal AM, et al. Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cells. J Immunother 2010;33:40-52.
  6. Simma O, Zebedin E, Neugebauer N, et al. Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. Cancer Res 2009;69:203-11.
  7. Jurgens B, Hainz U, Fuchs D, Felzmann T, Heitger A. Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood 2009;114:3235-43.
  8. Dohnal AM, Luger R, Paul P, Fuchs D, Felzmann T. CD40 ligation restores type 1 polarizing capacity in TLR4-activated dendritic cells that have ceased interleukin-12 expression. J Cell Mol Med 2009;13:1741-50.
  9. Dohnal AM, Graffi S, Witt V, et al. Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines. J Cell Mol Med 2009;13:125-35.
  10. Dohnal AM, Witt V, Hugel H, Holter W, Gadner H, Felzmann T. Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy 2007;9:755-70.
  11. Dohnal AM, Inthal A, Felzmann T, et al. Leukemia-associated antigenic isoforms induce a specific immune response in children with T-ALL. Int J Cancer 2006;119:2870-7.
  12. Huttner KG, Breuer SK, Paul P, Majdic O, Heitger A, Felzmann T. Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells. Cancer Immunol Immunother 2005;54:67-77.
  13. Felzmann T, Huttner KG, Breuer SK, et al. Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses. Cancer Immunol Immunother 2005;54:769-80.
  14. Lehner M, Stockl J, Majdic O, et al. MHC class II antigen signaling induces homotypic and heterotypic cluster formation of human mature monocyte derived dendritic cells in the absence of cell death. Hum Immunol 2003;64:762-70.
  15. Felzmann T, Witt V, Wimmer D, et al. Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection. Cytotherapy 2003;5:391-8.
  16. Felzmann T, Gadner H, Holter W. Dendritic cells as adjuvants in antitumor immune therapy. Onkologie 2002;25:456-64.
  17. Lehner M, Felzmann T, Clodi K, Holter W. Type I interferons in combination with bacterial stimuli induce apoptosis of monocyte-derived dendritic cells. Blood 2001;98:736-42.
  18. Felzmann T, Buchberger M, Lehner M, et al. Functional maturation of dendritic cells by exposure to CD40L transgenic tumor cells, fibroblasts or keratinocytes. Cancer Lett 2001;168:145-54.
  19. Felzmann T, Buchberger M, Jechlinger M, Kircheis R, Wagner E, Gadner H. Xenogenization by tetanus toxoid loading into lymphoblastoid cell lines and primary human tumor cells mediated by polycations and liposomes. Cancer Lett 2000;161:241-50.
  20. Felzmann T, Ramsey WJ, Blaese RM. Anti-tumor immunity generated by tumor cells engineered to express B7-1 via retroviral or adenoviral gene transfer. Cancer Lett 1999;135:1-10.
  21. Kircheis R, Kichler A, Wallner G, et al. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther 1997;4:409-18.
  22. Felzmann T, Ramsey WJ, Blaese RM. Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1. Gene Ther 1997;4:1322-9.
  23. Felzmann T, Gisslinger H, Ludwig H. Immunological findings in patients with myelodysplastic syndrome. Leuk Lymphoma 1994;15:201-8.
  24. Felzmann T, Gisslinger H, Krieger O, Majdic O, Ludwig H, Koller U. Immunophenotypic characterization of myelomonocytic cells in patients with myelodysplastic syndrome. Br J Haematol 1993;84:428-35.
  25. Szekeres T, Fritzer M, Pillwein K, Felzmann T, Chiba P. Cell cycle dependent regulation of IMP dehydrogenase activity and effect of tiazofurin. Life Sci 1992;51:1309-15.
  26. Maurer D, Felzmann T, Holter W, Petera P, Smolen J, Knapp W. Evidence for the presence of activated CD4 T cells with naive phenotype in the peripheral blood of patients with rheumatoid arthritis. Clin Exp Immunol 1992;87:429-34.
  27. Gadd SJ, Felzmann T, Majdic O, et al. Phenotypic analysis of functionally associated molecules on peripheral blood and synovial fluid monocytes from arthritis patients. Rheumatol Int 1992;12:153-7.
  28. Maurer D, Fischer GF, Felzmann T, et al. Ratio of complement receptor over Fc-receptor III expression: a sensitive parameter to monitor granulocyte-macrophage colony-stimulating factor effects on neutrophils. Ann Hematol 1991;62:135-40.
  29. Felzmann T, Gadd S, Majdic O, et al. Analysis of function-associated receptor molecules on peripheral blood and synovial fluid granulocytes from patients with rheumatoid and reactive arthritis. J Clin Immunol 1991;11:205-12.
  30. Maurer D, Felzmann T, Knapp W. A single laser flow cytometry method to evaluate the binding of three antibodies. J Immunol Methods 1990;135:43-7.